Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-05-15
2007-05-15
Gambel, Phillip (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388100, C435S069100, C435S069600, C435S326000, C435S440000, C435S455000
Reexamination Certificate
active
10966673
ABSTRACT:
The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.
REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 5834597 (1998-11-01), Tso et al.
patent: 5994514 (1999-11-01), Jardieu et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6277375 (2001-08-01), Ward
patent: 6329511 (2001-12-01), Vasquez et al.
patent: 6528624 (2003-03-01), Idusogie et al.
patent: 6797493 (2004-09-01), Sun et al.
patent: 7083784 (2006-08-01), Dall'Acqua et al.
patent: 2001/0033842 (2001-10-01), Jardieu et al.
patent: 2002/0098193 (2002-07-01), Ward
patent: 2003/0003098 (2003-01-01), Strom
patent: 2003/0044858 (2003-03-01), Jardieu et al.
patent: 2005/0014934 (2005-01-01), Hinton et al.
patent: 2005/0032114 (2005-02-01), Hinton et al.
patent: 2005/0226884 (2005-10-01), Hinton et al.
patent: 2005/0278799 (2005-12-01), Hinton et al.
patent: 2006/0198640 (2006-09-01), Dall'Acqua et al.
patent: 1260521 (2002-11-01), None
patent: WO93/04173 (1991-08-01), None
patent: WO98/31229 (1995-04-01), None
patent: WO97/28267 (1996-02-01), None
patent: WO97/34631 (1996-03-01), None
patent: WO98/05787 (1996-06-01), None
patent: WO98/47531 (1997-04-01), None
patent: WO99/02709 (1997-07-01), None
patent: WO97/34621 (1997-09-01), None
patent: WO98/23289 (1998-06-01), None
patent: WO00/42072 (1999-01-01), None
patent: WO00/47625 (1999-02-01), None
patent: WO99/51642 (1999-10-01), None
patent: WO99/58572 (1999-11-01), None
patent: WO01/58957 (2000-02-01), None
patent: WO00/68381 (2000-11-01), None
patent: WO02/060919 (2002-08-01), None
patent: WO2004/092219 (2004-10-01), None
Ellison et al. PNAS. 1982, 79:1984-1988.
Attwood, Science 2000; 290:1-5 (html format).
Skolnick et al. Trends in Biotech. 2000; 18:(1):34-39.
Martin et al. Molecular Cell, 2001, 7:867-877.
Ghetie, Victor, et al. “Increasing the serum persistence of an IgG fragment by random mutagenesis”,Nature Biotechnology(1997) 15(7):637-640.
Hinton, Paul R., et al. “Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates”,The Journal of Biological Chemistry(2004) 279(8):6213-6216.
Achatz, et al. “The IgE antigen Receptor: a Key Regulator for the Production of IgE Antibodies”,Int. Arch. Allergy Immunol, (2001) 124(1-3):31-4.
Alegre, et al. “Effect of a single amino acid mutation on the activating and immunosuppressive properties of a humanized OKT3 monoclonal antibody”,J. Immunol. (1992) 148(11):3461-8.
Angal, et al. “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibode”,Mol. Immunol(1993) 30(1):105-8.
Armour, et al. “Recombinant human IgG molecules lacking Fcgamma receptor 1 binding and monoctye triggering activities”,Eur J. Immunol. (1999) 29(8):2613-24.
Armour, et al. The Contrasting IgG-Binding Interactions of Human and Herpes Simplex Virus Fc Receptors,Biochem Soc. Trans. (2002) 30(4):495-500.
Arya, et al. “Mapping of amino acid residues in the C mu 3 domain of mouse IgM important in macromolecular assembly and complement-dependent cytolysis”,J. Immunol(1994) 152(3):1206-12.
Batra, et al. “Insertion of Constant Region Domains of Human IgG1 into CD4-PE40 Increases Its Plasma Half-Life”,Molec. Immunol. (1993) 30(4):379-386.
Brekke, et al. “Human IgG isotype-specific amino acid residues affecting complment-mediated cell lysis and phagocytosis”,Eur. J. Immunol. (1994) 24(10):2542-7.
Burmeister, et al. Crystal structure of the complex of rat neonatal Fc receptor with FcNature(1994) 372:379-383.
Canfield “The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region”,J. Exp. Med. (1991) 173(6):1483-91.
Caron, et al. “Engineered humanized dimeric forms of IgG are more effective antibodies”,J. Exp. Med. (1992) 176(4): 1191-5.
Chapman, et al. “Characterization of the Interaction Between the Herpes Simplex Virus Type 1 Fc Receptor and Immunoglobulin G”,J. Biol. Chem. (1999) 274(11):6911-9.
Chappel, et al. “Identification of a secondary Fc gamma R1 binding site within a genetically engineered human IgG antibody”,J. Biol. Chem. (1993) 268(33): 25124-31.
Chaudhury, et al. “The Major Histocompatibility Complex-related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its Lifespan”,J. Exp. Med. (2003) 197(3):315-322.
Chintalacharuvu, et al. “Hybrid IgA2/IgG1 Antibodies with Tailor-Made Effector Functions”,Clin. Imm. (2001) 101(1):21-31.
Cole, et al. “HuM291, A Humanized Anti-CD3 Antibody, is Immunosuppressive to T cells While Exhibiting Reduced Mitogenicity in Vitro”,Transplantation(1999) 68(4):563-71.
Cole, et al. “Human IgG2 variants of chimerical anti-CD3 are nonmitogenic to T cells”,J. Immunol. (1997) 159(7): 3613-21.
Dall'acqua, et al. “Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences”,J. Immunol. (2002) 169(9):5171-80.
Deisenhofer “Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A fromStaphylococcus aureusat 2.9- and 2.8-A resolution”,Biochemistry(1981) 20:2361-2370.
Delano, et al. “Convergent Solutions to Binding at a Protein-Protein Interface”,Science(2000) 287(5456):1279-83.
Dorai, et al. “Role of inter-heavy and light chain disulfide bonds in the effector functions of human immunoglobulin IgG1”,Mol. Immunol. (1992) 29(12):1487-91.
Duncan, et al. “The binding site for C1q on IgG”,Nature(1988) 332(6166):738-40.
Ehrlich, et al. “Characterization of human monoclonal antibodies directed against hepatitis B surface antigen”,Hum. Antibodies Hybridomas(1992) 3:2-7.
El-Amine, et al. “In Vivo Induction of Tolerance by an Ig Peptide is not Affected by the Deletion of FcR or a Mutated IgG Fc Fragment”,Int. Immunol. (2002) 14(7):761-6.
Firan, et al. “The MHC Class I-Related Receptor FcRn, Plays an Essential Role in the Matermofetal Transfer of Gamma-Globulin in Humans”,Int. Immunol. (2001) 13(8):993-1002.
Ghetie and Ward “Multiple roles for the major histocompatibility complex class I-related receptor FcRn”,Annu. Rev. Immunol. (2000) 18:739-766.
He X-y, et al. “Humanization and Pharmacokinetics of a Monoclonal Antibody with Specificity for Both E- and P-selectin”,The American Association of Immunologists(1998).
Helm, et al. “Identification of the high affinity receptor binding region in human immunoglobulin E”,J. Biol. Chem. (1996) 271(13): 7494-500.
Hezareh, et al. “Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody Against Human Immunodeficiency Virus Type”,J. Virol. (2001) 75(24):12161-8.
Hornick, et al. “Single Amino Acid Substitution in the Fc Region of Chimeric TNT-3 Antibody Accelerates Clearance and Improves Immunoscintigraphy of Solid Tumors”,J. Nucl. Med. (2000) 41(2):355-62.
Isaacs, et al. “Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function”, .J. Immunol. (1998) 161(8):3862-9.
Ito, et al. “[An amino acid substitution determining G1m(x) allotypic]”,Nippon Hoigaku Zasshi(1989) 43(2):155-60.
Jendeberg, et al. “Engineering of Fc(1) and Fc(3) from human immunoglobulin G to analyse subclass specificty for staphylococcal protein A”,J. Immunol Methods(1997) 201(1):25-34.
Jollifee, “Humanized antibodies: e
Hinton Paul R.
Tsurushita Naoya
Crowder Chun
Gambel Phillip
PDL Biopharma, Inc.
LandOfFree
Alteration of Fc-fusion protein serum half-lives by mutagenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alteration of Fc-fusion protein serum half-lives by mutagenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alteration of Fc-fusion protein serum half-lives by mutagenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3791254